Eikonizo Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $40M

  • Investors
  • 6

Eikonizo Therapeutics General Information

Description

Developer of small molecule therapeutic drugs designed to treat neurodegenerative disease. The company employs various gene therapy techniques, including viral vectors, to deliver corrected genes or gene-modifying agents to target cells in the body, enabling researchers to develop life-changing therapies by creating brain-penetrant and peripherally restricted small molecules to improve the treatment of human disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 245 Main Street
  • 2nd Floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Eikonizo Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eikonizo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 04-Dec-2023 $40M 000.00 0000 Completed Pre-Clinical Trials
5. Grant 30-Sep-2020 00000 00.00 Completed Pre-Clinical Trials
4. Grant 01-Sep-2020 00000 00.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 11-Apr-2020 000.00 Cancelled Pre-Clinical Trials
2. Accelerator/Incubator $6.1M Completed Pre-Clinical Trials
1. Seed Round 16-May-2018 $6.1M $6.1M 000.00 Completed Startup
To view Eikonizo Therapeutics’s complete valuation and funding history, request access »

Eikonizo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed-2 2,105,972 $0.000100 4% $2.23 $2.23 1x $1.79 3.95%
Seed 2,000,000 $0.000100 4% $1 $1 1x $0.94 3.19%
To view Eikonizo Therapeutics’s complete cap table history, request access »

Eikonizo Therapeutics Patents

Eikonizo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230322747-A1 Oxadiazole hdac6 inhibitors and uses thereof Pending 08-Apr-2022 0000000000
US-20240174616-A1 Hdac6 inhibitors and uses thereof Pending 03-Feb-2021 0000000000
JP-2022543106-A Hdac6 inhibitors and their uses Pending 30-Jul-2019 0000000000
US-20220281814-A1 Hdac6 inhibitors and uses thereof Pending 30-Jul-2019 0000000000
EP-4003319-A2 Hdac6 inhibitors and uses thereof Pending 30-Jul-2019 C07D205/12
To view Eikonizo Therapeutics’s complete patent history, request access »

Eikonizo Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Rick Lundberg President, Chief Executive Officer & Director
Janice Kranz Ph.D Co-Founder & Principal
Frederick Schroeder Ph.D Co-Founder & Director of Research & Development
William Shaw JD Co-Founder
Steve Tregay Ph.D Chairman
You’re viewing 5 of 8 executive team members. Get the full list »

Eikonizo Therapeutics Board Members (3)

Name Representing Role Since
Kevin Kinsella Self Board Member 000 0000
Steve Tregay Ph.D Eikonizo Therapeutics Chairman 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Eikonizo Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eikonizo Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mission BioCapital Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
Kevin Kinsella Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Eikonizo Therapeutics FAQs

  • When was Eikonizo Therapeutics founded?

    Eikonizo Therapeutics was founded in 2017.

  • Who is the founder of Eikonizo Therapeutics?

    Janice Kranz Ph.D, Frederick Schroeder Ph.D, William Shaw JD, and Jacob Hooker Ph.D are the founders of Eikonizo Therapeutics.

  • Who is the CEO of Eikonizo Therapeutics?

    Rick Lundberg is the CEO of Eikonizo Therapeutics.

  • Where is Eikonizo Therapeutics headquartered?

    Eikonizo Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Eikonizo Therapeutics?

    Eikonizo Therapeutics has 10 total employees.

  • What industry is Eikonizo Therapeutics in?

    Eikonizo Therapeutics’s primary industry is Drug Discovery.

  • Is Eikonizo Therapeutics a private or public company?

    Eikonizo Therapeutics is a Private company.

  • What is the current valuation of Eikonizo Therapeutics?

    The current valuation of Eikonizo Therapeutics is 0000.

  • What is Eikonizo Therapeutics’s current revenue?

    The current revenue for Eikonizo Therapeutics is 000000.

  • How much funding has Eikonizo Therapeutics raised over time?

    Eikonizo Therapeutics has raised $46.1M.

  • Who are Eikonizo Therapeutics’s investors?

    Mission BioCapital, National Institutes of Health, Alzheimers Drug Discovery Foundation, F-Prime Capital, and Kevin Kinsella are 5 of 6 investors who have invested in Eikonizo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »